Dual inhibition of CDK4/6 and IL-6 pathways as a novel therapeutic approach for triple-negative breast cancer cells

被引：0
|
作者：
Caroland, Kailey
Shi, Changyou
Lo, Hui-Wen
Lin, Jiayuh
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-4610
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4610
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Lapatinib induces IL-6 expression via MAPK pathway in triple-negative breast cancer cells
    Hsiao, Yu-Chun
    Chen, Yun-Ju
    Tang, Chih-Hsin
    Huang, Wei-Chien
    CANCER RESEARCH, 2014, 74 (19)
  • [42] Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
    J L Dean
    C Thangavel
    A K McClendon
    C A Reed
    E S Knudsen
    Oncogene, 2010, 29 : 4018 - 4032
  • [43] Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
    Dean, J. L.
    Thangavel, C.
    McClendon, A. K.
    Reed, C. A.
    Knudsen, E. S.
    ONCOGENE, 2010, 29 (28) : 4018 - 4032
  • [44] CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib
    Laderian, Bahar
    Fojo, Tito
    SEMINARS IN ONCOLOGY, 2017, 44 (06) : 395 - 403
  • [45] CREBBP alterations lead to CDK4/6 inhibitor sensitivity in triple negative breast cancer
    Natrajan, Rachael
    CANCER RESEARCH, 2020, 80 (04)
  • [46] Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A
    Kuo, Yueh-Hsiung
    Chiang, En-Pei Isabel
    Chao, Che-Yi
    Rodriguez, Raymond L.
    Chou, Pei-Yu
    Tsai, Shu-Yao
    Pai, Man-Hui
    Tang, Feng-Yao
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (03) : 480 - 493
  • [47] CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard
    Wolff, Antonio C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20): : 1993 - 1995
  • [48] Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition
    Demirsoy, Seyma
    Tran, Ha
    Liu, Joseph
    Li, Yunzhan
    Yang, Shengyu
    Aregawi, Dawit
    Glantz, Michael J.
    Jacob, Naduparambil K.
    Walter, Vonn
    Schell, Todd D.
    Olmez, Inan
    CANCERS, 2024, 16 (12)
  • [49] Combined inhibition of CDK4/6 and AKT is effective in Rb-intact triple-negative breast cancer of the luminal androgen receptor (LAR) subtype
    Kim, Gun Min
    Lee, Kyung-min
    Sudhan, Dhivya
    Lin, Albert
    Marin, Arnaldo
    Chatterjee, Sumanta
    Ye, Dan
    Kandagatla, Vishal
    Mendiratta, Saurabh
    Hanker, Ariella
    Arteaga, Carlos
    CANCER RESEARCH, 2022, 82 (04)
  • [50] Phase IB/II trial of palbociclib and binimetinib in advanced triple-negative breast cancer with hyperactivation of ERK and/or CDK4/6
    Manso, Luis
    Cortes, Alfonso
    Cejalvo, Juan M.
    Morales, Serafin
    Saenz, Jose A. Garcia
    Colomer, Ramon
    Sanchez-Bayona, Rodrigo
    Silva, Jorge
    Guerra, Juan A.
    Malon, Diego
    Mouron, Silvana
    Caleiras, Eduardo
    Quintela-Fandino, Miguel
    CANCER RESEARCH, 2022, 82 (04)
12345